EP1007048A4 - Identification d'agents utiles dans le traitement de la maladie d'alzheimer - Google Patents
Identification d'agents utiles dans le traitement de la maladie d'alzheimerInfo
- Publication number
- EP1007048A4 EP1007048A4 EP98911551A EP98911551A EP1007048A4 EP 1007048 A4 EP1007048 A4 EP 1007048A4 EP 98911551 A EP98911551 A EP 98911551A EP 98911551 A EP98911551 A EP 98911551A EP 1007048 A4 EP1007048 A4 EP 1007048A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- alzheimer
- disease
- identification
- treatment
- agents useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81612297A | 1997-03-11 | 1997-03-11 | |
| US816122 | 1997-03-11 | ||
| PCT/US1998/004683 WO1998040071A1 (fr) | 1997-03-11 | 1998-03-11 | Identification d'agents utiles dans le traitement de la maladie d'alzheimer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1007048A1 EP1007048A1 (fr) | 2000-06-14 |
| EP1007048A4 true EP1007048A4 (fr) | 2004-09-22 |
Family
ID=25219748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP98911551A Withdrawn EP1007048A4 (fr) | 1997-03-11 | 1998-03-11 | Identification d'agents utiles dans le traitement de la maladie d'alzheimer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1007048A4 (fr) |
| JP (1) | JP2001514661A (fr) |
| AU (1) | AU748768B2 (fr) |
| CA (1) | CA2284170C (fr) |
| WO (1) | WO1998040071A1 (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743771B2 (en) * | 1995-12-29 | 2004-06-01 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
| US7045531B1 (en) | 1997-03-11 | 2006-05-16 | The General Hospital Corporation | Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator |
| EP1007040B1 (fr) | 1997-08-21 | 2002-05-08 | P.N. Gerolymatos S.A. | Utilisation de phanquinone dans le traitement de la maladie d'alzheimer |
| US6316269B1 (en) | 1997-10-06 | 2001-11-13 | The General Hospital Corporation | Methods for screening drugs to predict tardive dyskinesia |
| US6638711B1 (en) * | 1999-04-29 | 2003-10-28 | The General Hospital Corporation | Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation |
| US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| CN1324234A (zh) | 1998-09-25 | 2001-11-28 | 格利科克斯有限公司 | 果糖胺氧化酶,拮抗剂和抑制剂 |
| ES2234559T3 (es) | 1999-01-07 | 2005-07-01 | P.N. Gerolymatos S.A. | Empleo de la fanquinona para el tratamiento o prevencion del deterioro de la memoria. |
| DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
| EP1571158B1 (fr) * | 1999-08-04 | 2009-10-14 | University Of Southern California | Assemblage de protéine amyloide beta globulaire et ses utilisations |
| US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| US7592304B2 (en) | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| US20030138374A1 (en) * | 2000-03-22 | 2003-07-24 | Yukitsuda Kudo | Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same |
| AUPR976401A0 (en) * | 2001-12-27 | 2002-01-31 | Alzhyme Pty Ltd | Agents for the treatment of alzheimer's disease and screening methods for the same |
| AU2002351880B2 (en) * | 2001-12-27 | 2007-08-30 | Neuroscientific Biopharmaceuticals Pty Ltd | Screening methods and the use of agents identified using the same |
| CA2478997C (fr) | 2002-03-08 | 2013-12-17 | Protemix Corporation Limited | Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque |
| AU2003258909B2 (en) | 2002-08-20 | 2010-07-08 | Philera New Zealand Limited | Dosage forms and related therapies |
| US20070185072A1 (en) * | 2003-03-21 | 2007-08-09 | Christophe Boldron | Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications |
| CN102293746A (zh) * | 2003-09-09 | 2011-12-28 | 吉里德科学公司 | 治疗性脂质体 |
| EP1694317A4 (fr) * | 2003-12-19 | 2010-05-12 | Protemix Corp Ltd | Composes antagonistes du cuivre |
| EP1778618B1 (fr) | 2004-07-19 | 2013-12-25 | PhilERA New Zealand Limited | Synthese de triethylenetetramines |
| MX2007001559A (es) | 2004-08-03 | 2007-04-10 | Transtech Pharma Inc | Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso. |
| SG171670A1 (en) | 2006-05-05 | 2011-06-29 | Transtech Pharma Inc | Rage fusion proteins, formulations, and methods of use thereof |
| US8338089B2 (en) | 2006-11-20 | 2012-12-25 | The Johns Hopkins University | Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity |
| ES2564634T3 (es) | 2007-06-14 | 2016-03-28 | Galactica Pharmaceuticals, Inc. | Proteínas de fusión de RAGE |
| EP2259782A4 (fr) * | 2008-03-03 | 2013-01-23 | Nad Life Pty Ltd | Formulations pharmaceutiques de resvératrol et procédés d'utilisation de celles-ci pour traiter des troubles cellulaires |
| EP2421892A1 (fr) | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Contrôle de la glycosylation de protéines, compositions et méthodes associées |
| WO2018236221A2 (fr) * | 2017-06-03 | 2018-12-27 | Can Holding B.V. | Dissolution de dépôt de peptide neurodégénératif |
| KR102048846B1 (ko) * | 2017-11-20 | 2019-11-27 | 한국생명공학연구원 | 혈관 질환 치료제 및 이의 스크리닝 방법 |
| US20220313647A1 (en) * | 2019-07-25 | 2022-10-06 | Tokyo University Of Science Foundation | Agent for treating, preventing or improving psychiatric and nervous system disorders or symptoms |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0681844A1 (fr) * | 1993-11-30 | 1995-11-15 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Substance pour detecter le depot d'amyloide |
| WO1998009523A1 (fr) * | 1996-09-05 | 1998-03-12 | Massachusetts Institute Of Technology | Compositions et procedes de traitement de troubles neurologiques et de maladies neurodegeneratives |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| CA2123211C (fr) * | 1991-11-12 | 2008-09-16 | Colin L. Masters | Methode de depistage et de traitement de la maladie d'alzheimer |
| US5688516A (en) * | 1992-11-12 | 1997-11-18 | Board Of Regents, The University Of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
| US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| CA2214247C (fr) * | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulateurs de l'agregation de substances amyloides |
-
1998
- 1998-03-11 AU AU65484/98A patent/AU748768B2/en not_active Ceased
- 1998-03-11 JP JP53971898A patent/JP2001514661A/ja not_active Ceased
- 1998-03-11 WO PCT/US1998/004683 patent/WO1998040071A1/fr not_active Ceased
- 1998-03-11 EP EP98911551A patent/EP1007048A4/fr not_active Withdrawn
- 1998-03-11 CA CA002284170A patent/CA2284170C/fr not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0681844A1 (fr) * | 1993-11-30 | 1995-11-15 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Substance pour detecter le depot d'amyloide |
| WO1998009523A1 (fr) * | 1996-09-05 | 1998-03-12 | Massachusetts Institute Of Technology | Compositions et procedes de traitement de troubles neurologiques et de maladies neurodegeneratives |
Non-Patent Citations (2)
| Title |
|---|
| BACON ET AL: "Rheumatoid Diesease, Amyloidosis and its Treatment with Penicillamine", EUROPEAN JOURNAL OF RHEUMATOLOGY AND INFLAMMATION, CAMERON PUBLISHERS, CASTLETOWN, GB, vol. 3, no. 2, 1979, pages 70 - 74, XP002117959, ISSN: 0104-1610 * |
| See also references of WO9840071A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6548498A (en) | 1998-09-29 |
| CA2284170A1 (fr) | 1998-09-17 |
| EP1007048A1 (fr) | 2000-06-14 |
| WO1998040071A1 (fr) | 1998-09-17 |
| JP2001514661A (ja) | 2001-09-11 |
| AU748768B2 (en) | 2002-06-13 |
| CA2284170C (fr) | 2008-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1007048A4 (fr) | Identification d'agents utiles dans le traitement de la maladie d'alzheimer | |
| CY2018020I1 (el) | Θεραπεια της νοσου ρομρε | |
| EP0963219A4 (fr) | Manipulations de stress nitrosant et oxydatif dans le traitement d'une maladie | |
| FI962557L (fi) | PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa | |
| FI964284L (fi) | Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito | |
| FI933946A7 (fi) | Hypoglykeemisinä aineina ja Alzheimerin taudin hoidossa käyttökelpoisia yhdisteitä | |
| EP1043991A4 (fr) | Traitement contre la maladie d'alzheimer | |
| EP0988265A4 (fr) | Traitement d'aromatiques lourds | |
| FI20000720L (fi) | Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi | |
| PL348226A1 (en) | Compounds for the antemortem diagnosis of alzheimer's disease and in vivo | |
| HUP0003852A3 (en) | Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias | |
| AP2001002102A0 (en) | Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas | |
| NO20001869D0 (no) | Fremgangsmõte for behandling av Alzheimerssykdom | |
| ZA978557B (en) | Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease. | |
| ID27576A (id) | Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun | |
| BR9711225A (pt) | Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer | |
| DE69604228D1 (de) | Pupillen Messanordnung und Alzheimer Krankheits Diagnosesystem | |
| IL117695A0 (en) | Pharmaceutical agents for the treatment of alzheimer's disease | |
| AU5550800A (en) | Diagnosis and treatment of alzheimer's disease | |
| DE69825888D1 (de) | Diagnostisches verfahren der alzheimer-erkrankung | |
| EP1030680A4 (fr) | Traitement de la maladie de kaposi avec il-12 | |
| FR2774596B1 (fr) | Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer | |
| DZ3320A1 (fr) | Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine | |
| EP0866799A4 (fr) | Apolipoproteine e2 et traitement de la maladie d'alzheimer | |
| EP0981545A4 (fr) | Traitement de l'osteoporose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19991007 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 25/28 B Ipc: 7A 01N 59/08 B Ipc: 7A 01N 43/60 B Ipc: 7A 01N 43/40 B Ipc: 7A 01N 43/38 B Ipc: 7A 01N 43/32 B Ipc: 7A 01N 43/00 B Ipc: 7A 01N 37/18 B Ipc: 7A 01N 37/12 B Ipc: 7A 61K 49/00 B Ipc: 7A 61K 38/17 B Ipc: 7A 61K 31/545 A |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20040811 |
|
| 17Q | First examination report despatched |
Effective date: 20050421 |
|
| 17Q | First examination report despatched |
Effective date: 20050421 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20081212BHEP Ipc: A61K 38/17 20060101ALI20081212BHEP Ipc: A61K 31/545 20060101AFI20081212BHEP |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20090721 |